Sancuso (granisetron)
- Region
- 🇪🇺 EU
- Active substance
- granisetron
- Company
- Grünenthal GmbH
- Status
- Authorised
- Therapeutic area
- Vomiting; Cancer
- EU approval
- Fri 20 Apr 2012
- Application
- EMEA/H/C/002296
- ATC
- A04AA02
- Official record
- www.ema.europa.eu
Indication
Prevention of nausea and vomiting in patients receiving moderately or highly emetogenic chemotherapy, with or without cisplatin, for up to five consecutive days. Sancuso may be used in patients receiving their first chemotherapy regimen or in patients who have previously received chemotherapy.
Regulatory milestones
No milestones recorded in the last year.
Follow Sancuso
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.